{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"BCTX","limit":50},"count":50,"signals":[{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"expanding operations effectively. Any failure to implement cohesive management and operating systems, to add resources on a cost-effective basis or to properly manage BriaPros expansion could have a material adverse effect on its business and results of operations. *Reliance on Third Parties* BriaPro does not expect to have any in-house manufacturing, pharmaceutical development or marketing capability. To be successful","filed_date":"2026-03-31","accession":"0001493152-26-014156","full_text":"https://origin.rootz.global/static/filing/0001493152-26-014156.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":33,"context":"Business Startups Act* of 2012 (the **JOBS Act**). In addition, as an emerging growth company, we are not required to conduct votes seeking approval, on an advisory basis, of the compensation of our named executive officers or the frequency with which such votes must be conducted. We may take advantage of these exemptions until the last day of the fiscal year in which the fifth anniversary of our initial public offerin","filed_date":"2026-02-12","accession":"0001493152-26-006390","full_text":"https://origin.rootz.global/static/filing/0001493152-26-006390.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"expanding operations effectively. Any failure to implement cohesive management and operating systems, to add resources on a cost-effective basis or to properly manage BriaPros expansion could have a material adverse effect on its business and results of operations. *Reliance on Third Parties* BriaPro does not expect to have any in-house manufacturing, pharmaceutical development or marketing capability. To be successful","filed_date":"2025-12-29","accession":"0001493152-25-029363","full_text":"https://origin.rootz.global/static/filing/0001493152-25-029363.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"expanding operations effectively. Any failure to implement cohesive management and operating systems, to add resources on a cost-effective basis or to properly manage BriaPros expansion could have a material adverse effect on its business and results of operations. | 18 | | ** ** **Reliance on Third Parties** * * BriaPro does not expect to have any in-house manufacturing, pharmaceutical development or marketing capabil","filed_date":"2025-12-01","accession":"0001493152-25-025469","full_text":"https://origin.rootz.global/static/filing/0001493152-25-025469.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":62,"context":"rd-party relationships to ensure continuity and quality, some events beyond the Companys control could result in complete or partial failure of these goods and services. Any such failure could have a material adverse effect on the financial conditions and result of operation of the Company. | 30 | | Due to the complexity of the process of developing pharmaceutical products, the Companys business may depend on arrangemen","filed_date":"2025-10-16","accession":"0001493152-25-018212","full_text":"https://origin.rootz.global/static/filing/0001493152-25-018212.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"data analytics platform, The Single Interface , for clinical support and real-time data analysis. In May 2023, Prevail Partners, LLC (Prevail Partners), an investment fund and affiliate of InfoWorks invested $4 million in the company at a 20% premium to the trailing thirty (30) trading day volume-weighted average price of the common shares of the Company on the Nasdaq Stock Exchange. **Manufacturing** We do not own","filed_date":"2025-10-16","accession":"0001493152-25-018212","full_text":"https://origin.rootz.global/static/filing/0001493152-25-018212.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"expanding operations effectively. Any failure to implement cohesive management and operating systems, to add resources on a cost-effective basis or to properly manage BriaPros expansion could have a material adverse effect on its business and results of operations. *Reliance on Third Parties* BriaPro does not expect to have any in-house manufacturing, pharmaceutical development or marketing capability. To be successful","filed_date":"2025-06-18","accession":"0001641172-25-015516","full_text":"https://origin.rootz.global/static/filing/0001641172-25-015516.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"expanding operations effectively. Any failure to implement cohesive management and operating systems, to add resources on a cost-effective basis or to properly manage BriaPros expansion could have a material adverse effect on its business and results of operations. *Reliance on Third Parties* BriaPro does not expect to have any in-house manufacturing, pharmaceutical development or marketing capability. To be successful","filed_date":"2025-03-12","accession":"0001493152-25-010035","full_text":"https://origin.rootz.global/static/filing/0001493152-25-010035.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":21,"context":"Business Startups Act* of 2012 (the **JOBS Act**). In addition, as an emerging growth company, we are not required to conduct votes seeking approval, on an advisory basis, of the compensation of our named executive officers or the frequency with which such votes must be conducted. We may take advantage of these exemptions until the last day of the fiscal year in which the fifth anniversary of our initial public offerin","filed_date":"2024-12-17","accession":"0001493152-24-050399","full_text":"https://origin.rootz.global/static/filing/0001493152-24-050399.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"expanding operations effectively. Any failure to implement cohesive management and operating systems, to add resources on a cost-effective basis or to properly manage BriaPros expansion could have a material adverse effect on its business and results of operations. *Reliance on Third Parties* BriaPro does not expect to have any in-house manufacturing, pharmaceutical development or marketing capability. To be successful","filed_date":"2024-12-16","accession":"0001493152-24-050212","full_text":"https://origin.rootz.global/static/filing/0001493152-24-050212.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":58,"context":"ds through the issuance of new debt or equity or may adversely affect the terms upon which such capital may be available. The inability to obtain sufficient financing on acceptable terms could have a material adverse effect on the Companys financial condition, results of operations, and business prospects. **** The Company is actively pursuing strategies to mitigate these risks, focusing on transitioning towards revenue","filed_date":"2024-10-29","accession":"0001493152-24-042743","full_text":"https://origin.rootz.global/static/filing/0001493152-24-042743.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"d because of his experience as our President and Chief Executive Officer, as well as his depth of academic and industry experience. **Gadi Levin, CA, MBA**, Chief Financial Officer and Secretary, was appointed Chief Financial Officer and Secretary of the Company on February 1, 2016. Mr. Levin has also served as Chief Financial Officer and Director of Vaxil Bio Ltd since March 1, 2016, and as the Finance Director of Eco (Atlantic)","filed_date":"2024-10-29","accession":"0001493152-24-042743","full_text":"https://origin.rootz.global/static/filing/0001493152-24-042743.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"expanding operations effectively. Any failure to implement cohesive management and operating systems, to add resources on a cost-effective basis or to properly manage BriaPros expansion could have a material adverse effect on its business and results of operations. *Reliance on Third Parties* BriaPro does not expect to have any in-house manufacturing, pharmaceutical development or marketing capability. To be successful","filed_date":"2024-06-14","accession":"0001493152-24-023860","full_text":"https://origin.rootz.global/static/filing/0001493152-24-023860.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"expanding operations effectively. Any failure to implement cohesive management and operating systems, to add resources on a cost-effective basis or to properly manage BriaPros expansion could have a material adverse effect on its business and results of operations. *Reliance on Third Parties* BriaPro does not expect to have any in-house manufacturing, pharmaceutical development or marketing capability. To be successful","filed_date":"2024-04-02","accession":"0001493152-24-012774","full_text":"https://origin.rootz.global/static/filing/0001493152-24-012774.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":21,"context":"Business Startups Act* of 2012 (the **JOBS Act**). In addition, as an emerging growth company, we are not required to conduct votes seeking approval, on an advisory basis, of the compensation of our named executive officers or the frequency with which such votes must be conducted. We may take advantage of these exemptions until the last day of the fiscal year in which the fifth anniversary of our initial public offerin","filed_date":"2024-01-09","accession":"0001493152-24-001830","full_text":"https://origin.rootz.global/static/filing/0001493152-24-001830.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"expanding operations effectively. Any failure to implement cohesive management and operating systems, to add resources on a cost-effective basis or to properly manage BriaPros expansion could have a material adverse effect on its business and results of operations. *Reliance on Third Parties* BriaPro does not expect to have any in-house manufacturing, pharmaceutical development or marketing capability. To be successful","filed_date":"2023-12-14","accession":"0001493152-23-044891","full_text":"https://origin.rootz.global/static/filing/0001493152-23-044891.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":18,"context":"anding operations effectively. Any failure to implement cohesive management and operating systems, to add resources on a cost-effective basis or to properly manage the Companys expansion could have a material adverse effect on its business and results of operations. **BriaPro may not generate revenue as expected** We are a majority shareholder of BriaPro. BriaPro may not generate financial returns or may not yield the d","filed_date":"2023-10-25","accession":"0001493152-23-038298","full_text":"https://origin.rootz.global/static/filing/0001493152-23-038298.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":15,"context":"d because of his experience as our President and Chief Executive Officer, as well as his depth of academic and industry experience. **Gadi Levin, CA, MBA**, Chief Financial Officer and Secretary, was appointed Chief Financial Officer and Secretary of the Company on February 1, 2016. Mr. Levin has also served as Chief Financial Officer and Director of Vaxil Bio Ltd since March 1, 2016, and as the Finance Director of Eco (Atlantic)","filed_date":"2023-10-25","accession":"0001493152-23-038298","full_text":"https://origin.rootz.global/static/filing/0001493152-23-038298.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"expanding operations effectively. Any failure to implement cohesive management and operating systems, to add resources on a cost-effective basis or to properly manage BriaPros expansion could have a material adverse effect on its business and results of operations. *Reliance on Third Parties* * * BriaPro does not expect to have any in-house manufacturing, pharmaceutical development or marketing capability. To be succes","filed_date":"2023-10-25","accession":"0001493152-23-038297","full_text":"https://origin.rootz.global/static/filing/0001493152-23-038297.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":16,"context":"erferes or is inconsistent with the completion of the Arrangement and Plan of Arrangement, including any material change to the income tax laws of Canada, which would reasonably be expected to have a material adverse effect on any of BriaCell, the BriaCell Shareholders, or if the Arrangement is completed, SpinCo or the holders of SpinCo Shares; | | |  |  |  | | |  |  (h) |  the aggregate number of BriaCell Shares held,","filed_date":"2023-07-26","accession":"0001493152-23-025573","full_text":"https://origin.rootz.global/static/filing/0001493152-23-025573.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":30,"context":"Information *Licensing Agreement between Faller & Williams Technology LLC (***FWT***) and Sapientia Pharmaceuticals, Inc.*(**Sapientia**) On May 16, 2017, FWT and Sapientia (a subsidiary of BriaCell) entered into a licensing agreement (the Licensing Agreement). It is anticipated that the Licensing Agreement will be assigned and assumed by BriaPro from Sapientia on the closing of the Arrangement. FWT is the owner of certain patents","filed_date":"2023-07-26","accession":"0001493152-23-025573","full_text":"https://origin.rootz.global/static/filing/0001493152-23-025573.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":32,"context":"Business Startups Act* of 2012 (the **JOBS Act**). In addition, as an emerging growth company, we are not required to conduct votes seeking approval, on an advisory basis, of the compensation of our named executive officers or the frequency with which such votes must be conducted. We may take advantage of these exemptions until the last day of the fiscal year in which the fifth anniversary of our initial public offerin","filed_date":"2023-01-17","accession":"0001493152-23-001505","full_text":"https://origin.rootz.global/static/filing/0001493152-23-001505.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"visiting or traveling to our clinical trial sites because of the outbreak of COVID-19. In the event that clinical trial sites are slowed down or closed to enrollment in our trials, this could have a material adverse impact on our clinical trial plans and timelines. We are continuing to assess our business plans and the impact COVID-19 is having on our clinical trial timelines and our ability to recruit candidates for c","filed_date":"2022-10-28","accession":"0001493152-22-029742","full_text":"https://origin.rootz.global/static/filing/0001493152-22-029742.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":15,"context":"d because of his experience as our President and Chief Executive Officer, as well as his depth of academic and industry experience. **Gadi Levin, CA, MBA**, Chief Financial Officer and Secretary, was appointed Chief Financial Officer and Secretary of the Company on February 1, 2016. Mr. Levin has also served as Chief Financial Officer and Director of Vaxil Bio Ltd since March 1, 2016, and as the Finance Director of Eco (Atlantic)","filed_date":"2022-10-28","accession":"0001493152-22-029742","full_text":"https://origin.rootz.global/static/filing/0001493152-22-029742.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":96,"match_count":7,"context":"professionals and is expected to concentrate on engaging the pharmaceutical companies for the licensing of the new vaccine candidates. The loss of the services of any of these personnel could have a material adverse effect on the business of the Company. The Company may not be able to attract and retain personnel on acceptable terms given the intense competition for such personnel among high technology enterprises, inc","filed_date":"2022-10-28","accession":"0001493152-22-029741","full_text":"https://origin.rootz.global/static/filing/0001493152-22-029741.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"affected by the virus or are fearful of visiting or traveling to our clinical trial sites because of the outbreak of COVID-19. In the event that clinical trial sites are slowed down or closed to enrollment in our trials, this could have a material adverse impact on our clinical trial plans and timelines. We are continuing to assess our business plans and the impact COVID-19 is having on our clinical","filed_date":"2022-10-28","accession":"0001493152-22-029742","full_text":"https://origin.rootz.global/static/filing/0001493152-22-029742.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"ock options to directors, executive officers, employees and scientific advisory board members under the Omnibus Plan. The stock options have an exercise price of US$5.59, vest in equal quarterly installments beginning May 1, 2026, and expire on February 1, 2031. | | |  (ii) |  On February 18, 2026, the Company and BriaPro, announced that they have entered into a definitive purchase agreement (the Pur","filed_date":"2026-03-10","accession":"0001493152-26-009557","full_text":"https://origin.rootz.global/static/filing/0001493152-26-009557.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":64,"match_count":8,"context":"oped by the Company and its Subsidiaries (collectively, the **Regulatory Permits**), except for any of the foregoing that would not reasonably be expected to, individually or in the aggregate, have a material adverse effect on the assets, business or operations of the Company taken as a whole (a **Material Adverse Effect**); the Company is in compliance in all material respects with the requirements of the Regulatory Pe","filed_date":"2025-12-23","accession":"0001493152-25-028916","full_text":"https://origin.rootz.global/static/filing/0001493152-25-028916.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":43,"match_count":1,"context":"evention may reduce the demand for our product candidates; | | |  |  |  | | |  |  |  changes in the market for cancer treatment, new alliances between existing market participants and the entrance of new market participants may interfere with our market penetration efforts; | | |  |  |  | | |  |  |  third-party payors may not agree to reimburse patients for any or all of the purchase price of our products,","filed_date":"2025-10-16","accession":"0001493152-25-018212","full_text":"https://origin.rootz.global/static/filing/0001493152-25-018212.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":43,"match_count":1,"context":"evention may reduce the demand for our product candidates; | | |  |  |  | | |  |  |  changes in the market for cancer treatment, new alliances between existing market participants and the entrance of new market participants may interfere with our market penetration efforts; | | |  |  |  | | |  |  |  third-party payors may not agree to reimburse patients for any or all of the purchase price of our products,","filed_date":"2024-10-29","accession":"0001493152-24-042743","full_text":"https://origin.rootz.global/static/filing/0001493152-24-042743.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":38,"match_count":1,"context":"evention may reduce the demand for our product candidates; | | |  |  |  | | |  |  |  changes in the market for cancer treatment, new alliances between existing market participants and the entrance of new market participants may interfere with our market penetration efforts; | | |  |  |  | | |  |  |  third-party payors may not agree to reimburse patients for any or all of the purchase price of our products,","filed_date":"2023-10-25","accession":"0001493152-23-038298","full_text":"https://origin.rootz.global/static/filing/0001493152-23-038298.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":38,"match_count":1,"context":"evention may reduce the demand for our product candidates; | | |  |  |  | | |  |  |  changes in the market for cancer treatment, new alliances between existing market participants and the entrance of new market participants may interfere with our market penetration efforts; | | |  |  |  | | |  |  |  third-party payors may not agree to reimburse patients for any or all of the purchase price of our products,","filed_date":"2022-10-28","accession":"0001493152-22-029742","full_text":"https://origin.rootz.global/static/filing/0001493152-22-029742.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"require for the purpose of enabling Placement Agent Counsel to deliver an opinion to the Placement Agent, or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Public Securities and the Placement Agents Warrant as herein co","filed_date":"2025-12-23","accession":"0001493152-25-028916","full_text":"https://origin.rootz.global/static/filing/0001493152-25-028916.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"or trial sites for the clinical trials; delays in obtaining institutional review board and other regulatory approvals to commence a clinical trial; slower than anticipated patient recruitment and enrollment; negative or inconclusive results from clinical trials; unforeseen safety issues; uncertain dosing issues; an inability to monitor patients adequately during or after treatment; and problems with","filed_date":"2023-07-26","accession":"0001493152-23-025573","full_text":"https://origin.rootz.global/static/filing/0001493152-23-025573.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":28,"match_count":1,"context":"securities from trading on its exchange and we are unable to obtain listing on another national securities exchange, a reduction in some or all of the following may occur, each of which could have a material adverse effect on our shareholders: |  |  the liquidity of our common shares; | | |  |  the market price of our common shares; | | |  |  our ability to obtain financing for the continuation of our operations; | | |","filed_date":"2025-07-10","accession":"0001641172-25-018633","full_text":"https://origin.rootz.global/static/filing/0001641172-25-018633.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":24,"match_count":3,"context":"orth in Section 3 below. | | |  3. | Vesting and Exercise. The Option shall vest and become exercisable over years,  of which will vest after , and the remainder which will vest in equal monthly installments thereafter, provided, with respect to each vesting date, that the Optionee has not experienced a Termination Date prior to such date. There shall be no proportionate or partial vesting in the per","filed_date":"2026-02-12","accession":"0001493152-26-006390","full_text":"https://origin.rootz.global/static/filing/0001493152-26-006390.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":24,"match_count":3,"context":"imbursement, and access pressures from state Medicaid programs, private insurance programs and pharmacy benefit managers, and implementation of U.S. health care reform legislation is increasing these pricing pressures. The Affordable Care Act instituted comprehensive health care reform, and includes provisions that, among other things, reduce and/or limit Medicare reimbursement, require all individuals to have he","filed_date":"2025-10-16","accession":"0001493152-25-018212","full_text":"https://origin.rootz.global/static/filing/0001493152-25-018212.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":24,"match_count":3,"context":"reatments and are more likely to benefit from the Companys immunotherapy treatments. Under the terms of the agreement, Caris will help BriaCell with efficient patient identification, accelerating enrollment for its current Phase I/II clinical trial in advanced metastatic breast cancer of certain genetically defined subgroups. The partnership between BriaCell and Caris leverages Caris Right-In-Time (R","filed_date":"2023-03-16","accession":"0001493152-23-007796","full_text":"https://origin.rootz.global/static/filing/0001493152-23-007796.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":24,"match_count":3,"context":"ction 3 below. | | |  |  | | |  3. |  Vesting and Exercise. The Option shall vest and become exercisable over years, of which will vest after , and the remainder which will vest in equal monthly installments thereafter, provided, with respect to each vesting date, that the Optionee has not experienced a Termination Date prior to such date. There shall be no proportionate or partial vesting in the per","filed_date":"2023-01-17","accession":"0001493152-23-001505","full_text":"https://origin.rootz.global/static/filing/0001493152-23-001505.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":24,"match_count":3,"context":"reatments and are more likely to benefit from the Companys immunotherapy treatments. Under the terms of the agreement, Caris will help BriaCell with efficient patient identification, accelerating enrollment for its current Phase I/II clinical trial in advanced metastatic breast cancer of certain genetically defined subgroups. The partnership between BriaCell and Caris leverages Caris Right-In-Time (R","filed_date":"2022-12-14","accession":"0001493152-22-035452","full_text":"https://origin.rootz.global/static/filing/0001493152-22-035452.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":24,"match_count":3,"context":"Early Data of Bria-IMT with KEYTRUDA Combination Study** |  |  |  All 11 patients were very heavily pre-treated with a median of 5 prior systemic therapy regimens (such as chemotherapy) prior to enrollment in BriaCells Combination Study. | | |  |  |  These patients previously did not respond to a number of currently available therapies, and many had very weak immune systems, further emphasizing the","filed_date":"2022-10-28","accession":"0001493152-22-029741","full_text":"https://origin.rootz.global/static/filing/0001493152-22-029741.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":18,"match_count":1,"context":"ause of a new outbreak of COVID-19, or of a new variant thereof, or of another pandemic. In the event that clinical trial sites are slowed down or closed to enrolment in our trials, this could have a material adverse impact on our clinical trial plans and timelines. The Company currently believes that the execution of our clinical trials and research programs were delayed by at least one quarter due to COVID-19. Althoug","filed_date":"2023-06-14","accession":"0001493152-23-021287","full_text":"https://origin.rootz.global/static/filing/0001493152-23-021287.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":18,"match_count":1,"context":"f visiting or traveling to our clinical trial sites because of the outbreak of COVID-19. In the event that clinical trial sites are slowed down or closed to enrolment in our trials, this could have a material adverse impact on our clinical trial plans and timelines. The Company is continuing to assess its business plans and the impact COVID-19 is having on the Companys clinical trial timelines and the Companys ability t","filed_date":"2023-03-16","accession":"0001493152-23-007796","full_text":"https://origin.rootz.global/static/filing/0001493152-23-007796.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":18,"match_count":1,"context":"f visiting or traveling to our clinical trial sites because of the outbreak of COVID-19. In the event that clinical trial sites are slowed down or closed to enrolment in our trials, this could have a material adverse impact on our clinical trial plans and timelines. The Company is continuing to assess its business plans and the impact COVID-19 is having on the Companys clinical trial timelines and the Companys ability t","filed_date":"2022-12-14","accession":"0001493152-22-035452","full_text":"https://origin.rootz.global/static/filing/0001493152-22-035452.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":16,"match_count":2,"context":"ntion mechanism. Accordingly, the Board and the Compensation Committee have not identified any risks arising from the Companys compensation policies and practices that are reasonably likely to have a material adverse effect on the Company. *Base Salary* ** In the view of the Company, paying base salaries which are competitive in the markets in which the Company operates is a first step to attracting and retaining talent","filed_date":"2026-02-12","accession":"0001493152-26-006390","full_text":"https://origin.rootz.global/static/filing/0001493152-26-006390.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":16,"match_count":2,"context":"study is listed in ClinicalTrials.gov as **NCT03328026** under FDA-approved BB-IND 10312 under protocol BRI-ROL-001 at ten clinical sites throughout the United States. The study is now closed to enrollment. In the Phase 1 part of the study, the Bria-IMT regimen was dosed in combination with Keytruda in 11 patients and in 11 patients with retifanlimab, with one patient starting on the combination wit","filed_date":"2025-10-16","accession":"0001493152-25-018212","full_text":"https://origin.rootz.global/static/filing/0001493152-25-018212.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":16,"match_count":2,"context":"nnounced its ongoing pivotal Phase 3 clinical study (listed on ClinicalTrials.gov as NCT06072612) has consented over 100 and has enrolled over 75 patients. BriaCell anticipates completing patient enrollment in late 2025 or early 2026, and may report top line data as early as H1-2026. On April 24, 2025, BriaCell Confirmed 100% Resolution of Lung Metastasis with Bria-OTS (Figure 1). Complete resolution","filed_date":"2025-07-10","accession":"0001641172-25-018633","full_text":"https://origin.rootz.global/static/filing/0001641172-25-018633.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":16,"match_count":2,"context":"imbursement, and access pressures from state Medicaid programs, private insurance programs and pharmacy benefit managers, and implementation of U.S. health care reform legislation is increasing these pricing pressures. The Affordable Care Act instituted comprehensive health care reform, and includes provisions that, among other things, reduce and/or limit Medicare reimbursement, require all individuals to have he","filed_date":"2024-10-29","accession":"0001493152-24-042743","full_text":"https://origin.rootz.global/static/filing/0001493152-24-042743.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":16,"match_count":2,"context":"imbursement, and access pressures from state Medicaid programs, private insurance programs and pharmacy benefit managers, and implementation of U.S. health care reform legislation is increasing these pricing pressures. The Affordable Care Act instituted comprehensive health care reform, and includes provisions that, among other things, reduce and/or limit Medicare reimbursement, require all individuals to have he","filed_date":"2023-10-25","accession":"0001493152-23-038298","full_text":"https://origin.rootz.global/static/filing/0001493152-23-038298.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BCTX","company":"BriaCell Therapeutics Corp.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":16,"match_count":2,"context":"actively developing and delivering innovative solutions to revolutionize healthcare. Under the terms of the agreement, Caris will help BriaCell with efficient patient identification, accelerating enrollment for its current Phase I/II clinical trial in advanced metastatic breast cancer of certain genetically defined subgroups. The partnership between BriaCell and Caris leverages Caris Right-In-Time (R","filed_date":"2023-06-14","accession":"0001493152-23-021287","full_text":"https://origin.rootz.global/static/filing/0001493152-23-021287.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"34084a8bf89f6d62be33ea1ea846694251cfca63388c66a35f3f530199b3456b","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"b2a92a6cb2d2d41a83cf2b83dd11fc75573386dea1c42cbb2ffb75fb40d04d08","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":35,"hourly_limit":500,"remaining":465,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}